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Abstract We have determined the three dimensional structure 
of the complex of human cathepsin L and E-64, an irreversible 
inhibitor of cysteine proteases, at 2.5 A resolution. The overall 
structure was similar to that of other known cysteine proteases 
and apparently identical to the mature region of procathepsin L. 
The electron density for E-64 is clearly visible except for the 
guanidinobutane moiety. From comparison of the active sites of 
cathepsin L and B, we found the following: (1) The S' subsites of 
cathepsin L and B are totally different because of the 'occluding 
loop' lying on the end of the S' subsites of cathepsin B. (2) The S 2 
pocket of cathepsin L is shallow and narrow compared to that of 
cathepsin B. (3) The S 3 subsites of the two enzymes are more 
similar than the other subsites, but cathepsin L may accom-
modate a more bulky group at this site. Knowledge of the active 
site structure of cathepsin L should be helpful for the structure-
based design of potent and specific inhibitors which are of 
therapeutic importance. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cathepsin L is one of the major cysteine proteases ex-
pressed in animal tissues. Although the enzyme is well known 
as a lysosomal protease, there is increasing evidence that ca-
thepsin L may play extracellular roles of physiological impor-
tance, such as bone résorption [1] and thyroid hormone lib-
eration [2]. In addition, human cysteine proteases are 
implicated in the pathogenesis of several diseases including 
rheumatoid arthritis [3], osteoporosis, tumor metastasis [4] 
and periodontal diseases [5]. Therefore, potent and selective 
inhibitors of the cysteine proteases are expected to be good 
candidates for therapeutic agents. 
Since both cathepsin B and L are abundant species among 
the mammalian cysteine proteases, comparative studies of the 
active sites in both cathepsin L and B are strongly desired to 
aid the design of selective inhibitors. Crystal structures of 
cathepsin B have been determined for the human and rat 
enzymes in the presence or absence of a synthetic inhibitor 
[6-8]. Regarding cathepsin L, the three-dimensional structure 
of the proenzyme has been published recently [9]. We describe 
here the crystal structure of mature cathepsin L focusing on 
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its active site. This study will provide a reliable basis for 
understanding and predicting activities and specificities of in-
hibitors. 
2. Materials and methods 
Recombinant human procathepsin L was expressed in mouse mye-
loma cells, purified and processed to obtain the mature enzyme bound 
to E-64 as described by Nomura et al. [10]. Briefly, procathepsin L 
was secreted in culture media up to about 10 mg/1 concentration and 
was purified to homogeneity by series of column chromatographies. 
The precursor was processed to obtain the mature cathepsin L. This 
process was initiated by changing the pH to 4.0 and terminated by 
adding E-64. The complex was further purified by gel filtration. 
Crystallization was performed by hanging-drop vapor diffusion at 
6°C. Prismatic crystals were grown from a solution containing 18% 
(w/w) polyethylene glycol 6000, 0.1 M Bis-Tris HC1 pH 6.0, 0.1 M 
CaCl2. They belong to a space group ~?2{l{l\ with unit cell dimen-
sions a = 48.8 A, b = 103.9 A, c = 47.8 A. The asymmetric unit contains 
one molecule of the complex. 
X-ray data were collected at room temperature on a Rigaku R-
AXIS lie detector mounted on an RU-200 generator. Intensity data 
up to 2.5 A resolution were extracted and averaged by the program 
PROCESS (Rigaku) and used for structural analysis. The data set was 
99.1% complete and the merging R factor was 5.7%. 
The rotation and translation functions were calculated by the pro-
gram package MERLOT [11] with data between 8.0 and 4.0 A reso-
lution. We initially used the papain structure (PDB ID code: lppp) as 
a search model but failed to obtain an interprétable translation func-
tion map for any high peaks on the rotation function maps. Use of a 
hypothetical model of cathepsin L, which had been built by standard 
homology modeling methods with a papain structure as the template, 
led to successful determination of the position of cathepsin L in the 
crystal. The crystallographic R value for this model after rigid-body 
refinement was 0.604. 
X-PLOR [12] and QUANTA (Release 4.1, Molecular Simulations 
Inc.) were used for calculation of maps, revision of models and struc-
ture refinement. The parameter set of CHARMm (Release 23.1, Mo-
lecular Simulations Inc.) were used throughout the model building 
and structure refinement procedures. The R value of the current mod-
el is0.175 and the free R value is 0.249 for a data set between 8.0 to 
2.5 A resolution. The RMS deviations from the target values are 0.017 
A for bond lengths, 2.95° for bond angles, and 1.87° for improper 
torsion angles. The current model contains 63 water molecules. 
3. Results and discussion 
3.1. Structure of cathepsin L 
Most of the backbone structure became traceable during 
the refinement and manual model revision cycles, except for 
the nine residues from Phe-172 to Asn-180. (The sequence 
number of cathepsin L referred to in this report is based on 
the mature protein sequence which begins with Ala-114 of the 
preproprotein.) The electron density for these residues is not 
clear on a |2F 0 —F c | m a p calculated with the current model 
suggesting the flexible and disordered nature of this region. A 
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Fig. 1. Overall structures of human cathepsm L (a), papain (b) and 
human cathepsin B (c) drawn with MolScript [17]. N and C repre-
sent the amino and carboxyl termini, respectively. The catalytic cys-
teines are presented using the ball-and-stick model. The atomic co-
ordinates of papain and cathepsin B were taken from the 
Brookhaven Protein Data Bank entries 9pap and lhuc, respectively. 
similar disordered structure was also observed in the same 
region of procathepsin L [9]. 
As expected from the high sequence identity (41%), the 
overall structure of human cathepsin L is similar to that of 
papain (Fig. 1). Among the 220 residues of mature cathepsin 
L, 183 Coc atoms can be superimposed onto the corresponding 
Coc atoms of papain with an RMS deviation of 0.82 A. The 
only major difference is an extended loop corresponding to 
the sequence from Phe-172 to Asn-179 of cathepsin L. 
Though we could not model these residues, as mentioned 
above, they are distant from the active site of this enzyme. 
Molecular packing in the crystal shows that the missing res-
idues are also apart from the active sites of adjacent mole-
cules. Therefore, we may safely assume that there are no 
structural perturbations around the active site due to the miss-
ing residues. 
Coulombe et al. [9] have shown that the prosegment of 
procathepsin L consists of two components: the N-terminal 
globular domain and C-terminal extended structure. The for-
mer interacts with the loop from His-140 to Asp-155 of the 
mature domain, and the latter lies in the active site cleft. 
However, judging from the figures presented in the paper 
[9], there is no substantial difference in any part of the mature 
region between the precursor and mature form of cathepsin L. 
It seems that the tertiary structure formation of the mature 
cathepsin L is completed in the proenzyme, though precise 
studies based on the atomic coordinates remain to be per-
formed. 
3.2. Interactions between cathepsin L and E-64 
There are several crystallographic studies which have re-
vealed interactions between plant cysteine protease and E-
64. Varughese et al. [13] determined the crystal structure of 
the papain-E-64 complex and showed the first molecular view 
of the E-64 adduct bound with cysteine protease. The struc-
ture of the actinidin-E-64 complex was also determined [14]. 
Yamamoto et al. [15] and Kim et al. [16] reported that there 
are two binding modes for E-64-c, a synthetic derivative of E-
64, to complex with papain. 
The E-64 adduct interacts with cathepsin L via almost the 
same manner as found in papain and actinidin crystals. The 
carboxyl group of E-64 is in the oxyanion hole which consists 
of the side chains of Gin-16, Trp-189, His-163 and the main 
chain of Cys-25. There are six hydrogen bonds between E-64 
and cathepsin L. Three of them are found between the car-
boxyl group of E-64 and the residues forming the oxyanion 
hole. The other three seem to be important to fix the inhibitor 
in the active site cleft. The 05 and N10 atoms of E-64 form 
hydrogen bonds with Gly-68 like a parallel ß-sheet (Fig. 3). 
The N6 atom of E-64 is likely to be involved in a weak (3.4 A) 
hydrogen bond with the main chain carbonyl oxygen of Asp-
162. These hydrogen bonds are commonly observed in papain 
and actinidin accommodating E-64 or E-64-c. This may be a 
natural consequence because those residues are conserved not 
only in the amino acid sequences but also in the three-dimen-
sional structures of the three proteases. The 4-guanidinobu-
tane moiety of E-64 is not well defined in the final omit map 
(Fig. 2), and the atomic temperature factors of the guanidino 
group are greater than 60 A2. These indicate that this moiety 
is not fixed in the cleft. The side chain of the leucine moiety is 
located in the S2 pocket stretching down toward Met-70 and 
Ala-135. These residues, together with Leu-69, Met-161 and 
Gly-164, form the bottom of the hydrophobic S2 pocket. 
3.3. Comparison of active sites between cathepsin L and B 
As there is no evidence for distinguishing each subsite in the 
S' region of the cleft, we will refer to the S' subsites as the S' 
region as a whole. The S' region of cathepsin L is similar to 
that of papain and is well described as a shallow depression 
rather than a cleft. The indole ring of Trp-189 is located at the 
center serving as a flat floor. The floor is surrounded by the 
side chains of Gln-21, Gly-20, Asn-18, Glu-192, Trp-193 and 
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Fig. 2. Stereoview of an omit \F0—F0\ map showing the electron density of E-64. The map was phased by the final model without E-64 and 
contoured at the 2.5 a level. 
Leu-144. It is in the S' region that the most remarkable differ-
ence between the active sites of cathepsin L and B resides. As 
described by Musil et al. [6], cathepsin B bears the 'occluding 
loop' lying on the equivalent position to the S' region of 
cathepsin L. The loop corresponds to a long insertion se-
quence (106-124) in cathepsin B. This additional piece of 
structure not only accounts for the characteristic carboxydi-
peptidase activity of cathepsin B but also provides specific 
hooks (interaction points) for selective inhibitors. Actually, 
it has been revealed by X-ray analysis that a B selective in-
hibitor interacts with two histidine residues on the occluding 
loop [7]. Since the structural environments are totally differ-
ent, we may expect that a compound which could fit in the S' 
region of cathepsin L would not be a good inhibitor of ca-
thepsin B and vice versa. 
The S2 subsite of cathepsin L is deep and hydrophobic. 
These characteristics should be common in cysteine proteases 
which prefer bulky and hydrophobic residues at the P2 posi-
tion of the substrate. However, there are several substitutions 
of amino acid residues and conformational changes of a loop 
structure which make the shape of S2 pocket of cathepsin L 
different from that of cathepsin B. If we look down the active 
site cleft of cathepsin L, putting the primed subsites up and 
unprimed subsites down, like Fig. 4, Asp-162, Met-161, Asp-
160 and Ala-214 form a continuous wall on the right hand 
side of the S2 pocket. This wall makes the S2 pocket of ca-
thepsin L narrow and clear. In cathepsin B, there is no equiv-
alent residue for the Met-161 of cathepsin L. Consequently, 
the space corresponding to that residue is opened as a part of 
the S2 pocket. This is because the loop from Val-191 to Gly-
198 in cathepsin B (from Pro-154 to Asp-162 in cathepsin L) 
runs through a different route and the peptide strand is 
kinked at Gly-198. It should be noted that the main chain 
carbonyl oxygen of Met-161 of cathepsin L is exposed to 
the solvent. Although E-64 has no interaction with this oxy-
gen, it may be possible to utilize this hydrogen bond acceptor 
for designing cathepsin L selective inhibitors. At the bottom 
of the pocket, there is the side chain of Met-70 (Pro-76 for 
cathepsin B) lying across the cleft, which makes the S2 pocket 
of cathepsin L shallower than that of cathepsin B. 
By analogy with papain, the S3 subsite of cathepsin L can 
be assigned to a region in the middle of the left wall of the 
cleft (Fig. 4). There is an extended structure of Gly-67 and 
Gly-68 at the center of this subsite, surrounded by the side 
chains of Asn-66, Glu-63 and Leu-69 as well as the carbonyl 
oxygen of Gly-61. The S3 subsites of the two enzymes are 
more similar than the other regions in the active site cleft. 
However, the side chain of Tyr-75 in cathepsin B, which cor-
responds to Leu-69 in cathepsin L, makes the subsite nar-
rower than that of cathepsin L. Therefore, cathepsin L may 
accommodate a more bulky group in this region. 
Gly 68 (Oxyanion hole] 
" ^ \ Gin 19 
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Fig. 3. (a) Chemical structure and atom numbering of E-64. (b) 
Schematic diagram showing the interactions of E-64 adduct and sur-
rounding residues of cathepsin L. The guanidino group is not fixed 
in the crystal. 
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Fig. 4. Stereoview of the active site cleft of cathepsin L. E-64 atoms were omitted for simplicity. Dots represent the Connolly surface with sol-
vent radius of 1.4 A. 
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